TP53 and mesothelioma: Both mutations were found in sarcomatoid subtype tumours that did not have alterations in CDKN2A, BAP1 or NF2. In the TCGA-Meso cohort, only one patient with biphasic histology had a G12C KRAS hotspot mutation with a concurrent TP53 mutation but without alterations in other mesothelioma drivers, similar with our cohort.